Er komplette og nye data gode Þker sannsynligheten world wide. Er det dÄrligere data reduseres sannsynligheten. Er vel sÄ enkelt. Poenget er at nÄ kommer som det stÄr i meldingen the complete data will be released at EUROGIN i mars 2024. Og Asieris er is proactively preparing for New Drug Application (NDA) procedures.
Komplett data Cevira kommer fÞrst i mars. Og US og EU vil ogsÄ mÄtte forholde seg til det komplette datasettet for Ä vurdere NDA. Vurderes vel statistikk likt, men kan vel ha noe med gruppen ja.
Tror PHO skal vÊre mer enn fornÞyd om Cevira nÄ godkjennes for salg i Kina. Greit Ä fokusere pÄ det. Det er jo hvis det lykkes en innertier i biotek. Jeg kan ikke huske norsk biotek fÄtt til noe slikt siden Algeta?
Enhancing Leadership in Gynecology, Asieris Pharmaceuticals Appoints Sophia Cao to Lead the Newly-Established Womenâs Health Business Unit, Accelerating Strategic Expansion
Shanghai, China, January 8, 2024 â Asieris Pharmaceuticals (Stock code ïŒ688176.SH) has announced its set-up of the Womenâs Health Business Unit for commercialization. This strategic move is designed to enhance the companyâs focus on genitourinary diseases and strengthen its position in womenâs health. The new business unit will center around core asset APL-1702, a potentially first-in-class non-surgical treatment of cervical high-grade squamous intraepithelial lesions. Asieris Pharmaceuticals will leverage both in-house discoveries and external partnerships to enrich its gynecological portfolio, thereby reinforcing its leadership in womenâs health.
APL-1702, a photodynamic drug-device combination developed for the treatment of cervical high-grade squamous intraepithelial lesions (HSIL), has demonstrated positive results in the global international multi-center phase III clinical trial, and the complete data will be released at EUROGIN in March 2024. APL-1702 is on track to become the worldâs first product with proven efficacy in the non-surgical treatment of HSIL. The company is proactively preparing for New Drug Application (NDA) procedures.